ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Range, S.
Right arrow Articles by Kelly, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Range, S.
Right arrow Articles by Kelly, F.
Eur Respir J 1999; 13: 560-564
Copyright © ERS Journals Ltd 1999

Clinical Trial

Treatment of pulmonary exacerbations of cystic fibrosis leads to improved antioxidant status

SP Range, C Dunster, AJ Knox, and FJ Kelly

Many cystic fibrosis (CF) patients have increased circulating levels of oxidation products and/or decreased antioxidant status. This study investigated whether treatment of pulmonary exacerbations decreased oxidative stress in CF patients. Seventeen adult patients were studied at the beginning and end of treatment with intravenous antibiotics. Plasma concentrations of the antioxidants ascorbic acid, alpha-tocopherol, uric acid and total reduced thiols, together with plasma retinol, lipid hydroperoxides, malondialdehyde and protein carbonyl levels were determined. Median (interquartile range) pretreatment and post-treatment levels were compared using the Wilcoxon signed rank test. Clinical resolution was reflected by improved spirometry. Significant increases were observed in plasma ascorbic acid (pre 30.4 (15.7-38.6) microM, post 35.2 (27.3-49.6) microM), alpha-tocopherol (pre 19.7 (13.6-25.2) microM, post 25.2 (19.3-31.6) microM) and retinol (pre 1.9 (1.5-2.5) microM, post 2.7 (1.7-3.5) microM). No change in plasma total reduced thiols occurred following treatment (pre 409 (366-420) microM, post 392 (366-423) microM), whereas uric acid fell with treatment (pre 307 (274-394) microM, post 260 (216-317) microM). Neither plasma protein carbonyls or malondialdehyde levels altered with treatment (protein carbonyls pre 0.47 (0.28-1.27), post 0.67 (0.42-0.83) nM x mg protein(-1); malondialdehyde pre 0.75 (0.53-1.18), post 0.84 (0.65-1.15) microM). Lipid hydroperoxides levels did decrease following treatment (53 (18-85) versus 17 (10-55) nM). This study demonstrated that treatment of infective exacerbations resulted in increased plasma levels of some antioxidant vitamins. No immediate change in plasma protein oxidation was observed, but lipid oxidation was decreased.


This article has been cited by other articles:


Home page
 ChestHome page
V. Starosta, E. Rietschel, K. Paul, U. Baumann, and M. Griese
Oxidative Changes of Bronchoalveolar Proteins in Cystic Fibrosis.
Chest, February 1, 2006; 129(2): 431 - 437.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
E. I Back, C. Frindt, D. Nohr, J. Frank, R. Ziebach, M. Stern, M. Ranke, and H. K Biesalski
Antioxidant deficiency in cystic fibrosis: when is the right time to take action?
Am. J. Clinical Nutrition, August 1, 2004; 80(2): 374 - 384.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
L. G Wood, D. A Fitzgerald, P. G Gibson, D. M Cooper, and M. L Garg
Increased plasma fatty acid concentrations after respiratory exacerbations are associated with elevated oxidative stress in cystic fibrosis patients
Am. J. Clinical Nutrition, April 1, 2002; 75(4): 668 - 675.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the European Respiratory Society.